|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current assets: | ||||||
| Cash | ||||||
| Deferred offering costs associated with public offering | ||||||
| Short-term prepaid insurance | ||||||
| Total current assets | ||||||
| Marketable securities held in Trust Account | ||||||
| Long-term prepaid insurance | ||||||
| Total assets | ||||||
| Liabilities and Stockholders' Deficit: | ||||||
| Current liabilities: | ||||||
| Related party payable | ||||||
| Accrued expenses | ||||||
| Income tax payable | ||||||
| Franchise tax payable | ||||||
| Related party promissory note | ||||||
| Accrued offering and formation costs | ||||||
| Total current liabilities | ||||||
| Deferred underwriting commission | ||||||
| Total liabilities | ||||||
| Common stock subject to possible redemption; 2,714,202 shares at $10.20 per share at December 31, 2022 and 17,250,000 shares at $10.20 per share at December 31, 2021 | ||||||
| Common stock subject to possible redemption | ||||||
| Total common stock subject to possible redemption; 2,714,202 shares at $10.20 per share at December 31, 2022 and 17,250,000 shares at $10.20 per share at December 31, 2021 | ||||||
| Stockholders' Deficit: | ||||||
| Common stock, $0.0001 par value; 50,000,000 shares authorized; 4,908,700 issued and outstanding (excluding 2,714,202 and 17,250,000 shares subject to redemption) | ||||||
| Common stock not subject to possible redemption | ||||||
| Total common stock, $0.0001 par value; 50,000,000 shares authorized; 4,908,700 issued and outstanding (excluding 2,714,202 and 17,250,000 shares subject to redemption) | ||||||
| Additional paid-in capital | ||||||
| Accumulated deficit | ||||||
| Total stockholders' deficit | ||||||
| Total Liabilities and Stockholders' Deficit |
Loading...
